{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:44:15Z","timestamp":1763037855799,"version":"3.41.2"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Patients with heterozygous familial hypercholesterolemia (HeFH) are at increased risk for COVID-19 cardiovascular complications in the acute phase of the infection. Elevated levels of LDL-C and often lipoprotein(a) are present from birth and lead to endothelial dysfunction, which is aggravated by a direct viral attack of the endothelial cells and their exposure to the toxic levels of circulating proinflammatory and prothrombotic mediators during the hyperinflammatory reaction typical of COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Evidence to date shows the benefit of lipid-lowering therapy in patients with COVID-19. In HeFH patients who are at much higher cardiovascular risk, the focus should, therefore, be on the effective lowering of LDL-C levels, the root cause of the greater cardiovascular vulnerability to COVID-19 infection in these patients. The ongoing use of statins and other lipid-lowering therapies should be encouraged during the ongoing COVID pandemic to mitigate the risk of cardiovascular complications from COVID-19, particularly in HeFH patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Epidemiologic registry data show that the incidence of myocardial infarction is increased in SARS-CoV-2-infected HeFH patients. There is a need to study whether the risk for acute cardiovascular events is increased in the long-term and if there are changes in lipid metabolism after SARS-CoV infection(s) in patients with HeFH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000876","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T07:00:14Z","timestamp":1678950014000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19"],"prefix":"10.1097","volume":"34","author":[{"given":"Alpo","family":"Vuorio","sequence":"first","affiliation":[{"name":"Mehil\u00e4inen Airport Health Centre, Vantaa"},{"name":"Department of Forensic Medicine, University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Raal","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[{"name":"Wihuri Research Institute, Atherosclerosis Research Laboratory, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/d41586-023-00075-4","article-title":"China's COVID wave has probably peaked, model suggests","volume":"613","author":"Lewis","year":"2023","journal-title":"Nature"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12889-019-7212-4","article-title":"The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Public Health"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1126\/science.6261329","article-title":"Regulation of plasma cholesterol by lipoprotein receptors","volume":"212","author":"Brown","year":"1981","journal-title":"Science"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1161\/01.ATV.17.11.3127","article-title":"Familial hypercholesterolemia in the Finnish North Karelia. A molecular, clinical, and genealogical study","volume":"17","author":"Vuorio","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.amjcard.2017.08.012","article-title":"Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia","volume":"120","author":"Tada","year":"2017","journal-title":"Am J Cardiol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/biomedicines10092320","article-title":"The Influence of SARS-CoV-2 infection on lipid metabolism - the potential use of lipid-lowering agents in COVID-19 management","volume":"10","author":"Kowalska","year":"2022","journal-title":"Biomedicines"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"890141","DOI":"10.3389\/fphar.2022.890141","article-title":"Long-term cardiovascular and cerebrovascular challenges posed by COVID-19 in patients with familial hypercholesterolemia","volume":"13","author":"Vuorio","year":"2022","journal-title":"Front Pharmacol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/v15020533","article-title":"Post-COVID-19 syndrome comprehensive assessment: from clinical Ddagnosis to imaging and biochemical-guided diagnosis and management","volume":"15","author":"Yan","year":"2023","journal-title":"Viruses"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.redox.2018.09.024","article-title":"Fenofibrate improves vascular endothelial function and contractility in diabetic mice","volume":"20","author":"Xu","year":"2019","journal-title":"Redox Biol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S2213-8587(22)00389-8","article-title":"Blood lipids after COVID-19 infection","volume":"11","author":"Durrington","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12944-021-01563-0","article-title":"COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection","volume":"20","author":"Surma","year":"2021","journal-title":"Lipids Health Dis"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-021-00245-3","article-title":"Prevention of cardiovascular burden in COVID-19 patients suffering from familial hypercholesterolemia: a global challenge","volume":"11","author":"Vuorio","year":"2022","journal-title":"Cardiol Ther"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41591-022-02158-7","article-title":"The impact of the COVID-19 pandemic on cardiovascular disease prevention and management","volume":"29","author":"Dale","year":"2023","journal-title":"Nat Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"100197","DOI":"10.1016\/j.ajpc.2021.100197","article-title":"COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD","volume":"7","author":"Myers","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"669373","DOI":"10.3389\/fgene.2021.669373","article-title":"Editorial: genetics of familial hypercholesterolemia: new insight","volume":"12","author":"Vuorio","year":"2021","journal-title":"Front Genet"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI116983","article-title":"Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level","volume":"93","author":"Sorensen","year":"1994","journal-title":"J Clin Invest"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"Libby","year":"2020","journal-title":"Eur Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tcm.2020.10.005","article-title":"COVID-19 - a vascular disease","volume":"31","author":"Siddiqi","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"R22-20250729","first-page":"1","article-title":"Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies","author":"Xu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/biomedicines11010071","article-title":"Cardiovascular complications of viral respiratory infections and COVID-19","volume":"11","author":"Franczuk","year":"2022","journal-title":"Biomedicines"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2021.01.021","article-title":"Familial hypercholesterolaemia and COVID-19: a two-hit scenario for endothelial dysfunction amenable to treatment","volume":"320","author":"Vuorio","year":"2021","journal-title":"Atherosclerosis"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11883-020-00867-3","article-title":"Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis","volume":"22","author":"Moriarty","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2022.07.015","article-title":"Lipoprotein(a) during COVID-19 hospitalization: thrombosis, inflammation, and mortality","volume":"357","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"R28-20250729","first-page":"cvac195","article-title":"Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank","author":"Wan","year":"2023","journal-title":"Cardiovasc Res"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","article-title":"Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study","volume":"398","author":"Katsoularis","year":"2021","journal-title":"Lancet"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00395-016-0579-9","article-title":"Severe familial hypercholesterolemia impairs the regulation of coronary blood flow and oxygen supply during exercise","volume":"111","author":"Bender","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/FJC.0000000000001106","article-title":"Altered vascular reactivity to circulating angiotensin II in familial hypercholesterolemia","volume":"78","author":"Ekholm","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"15667","DOI":"10.1038\/s41598-021-95277-z","article-title":"A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients","volume":"11","author":"Drakos","year":"2021","journal-title":"Sci Rep"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/cvr\/cvaa230","article-title":"Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science","volume":"116","author":"Evans","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"e12718","DOI":"10.1111\/micc.12718","article-title":"Coronary microvascular dysfunction pathophysiology in COVID-19","volume":"28","author":"Yin","year":"2021","journal-title":"Microcirculation"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/00015385.2022.2067641","article-title":"The effect of prior COVID-19 infection on coronary microvascular dysfunction","volume":"77","author":"Bilge","year":"2022","journal-title":"Acta Cardiol"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"e12757","DOI":"10.1111\/micc.12757","article-title":"Coronary microvascular dysfunction is common in patients hospitalized with COVID-19 infection","volume":"29","author":"\u00c7ali\u015fkan","year":"2022","journal-title":"Microcirculation"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"e025844","DOI":"10.1161\/JAHA.122.025844","article-title":"Prior SARS-CoV-2 Infection is associated with coronary vasomotor dysfunction as assessed by coronary flow reserve from cardiac positron emission tomography","volume":"11","author":"Weber","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R39-20250729","first-page":"cvad006","article-title":"Differential impacts of COVID-19 variants on human microvascular function","author":"Nishijima","year":"2023","journal-title":"Cardiovasc Res"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.122.060632","article-title":"Myocardial involvement after hospitalization for COVID-19 complicated by troponin elevation: a prospective, multicenter, observational study","volume":"147","author":"Artico","year":"2023","journal-title":"Circulation"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1747493020972922","article-title":"Stroke in COVID-19: a systematic review and meta-analysis","volume":"16","author":"Nannoni","year":"2021","journal-title":"Int J Stroke"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/STROKEAHA.120.031786","article-title":"Acute ischemic stroke and COVID-19: an analysis of 27 676 patients","volume":"52","author":"Qureshi","year":"2021","journal-title":"Stroke"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00415-021-10837-7","article-title":"Ischemic stroke associated with COVID-19: a systematic review and meta-analysis","volume":"269","author":"Luo","year":"2022","journal-title":"J Neurol"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"1097229","DOI":"10.3389\/fcvm.2022.1097229","article-title":"SARS-CoV-2 infection predicts larger infarct volume in patients with acute ischemic stroke","volume":"9","author":"De Michele","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"106903","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106903","article-title":"COVID-19 independently predicts poor outcomes in acute ischemic stroke- insights from a multicenter study from Pakistan and United Arab Emirates","volume":"32","author":"Khan","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"106987","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.106987","article-title":"Increased stroke severity and mortality in patients with SARS-CoV-2 infection: an analysis from the N3C database","volume":"32","author":"Narrett","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/01.STR.19.9.1097","article-title":"Risk of brain infarction in familial hypercholesterolemia","volume":"19","author":"Kaste","year":"1988","journal-title":"Stroke"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1161\/01.STR.0000169920.64180.fa","article-title":"Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis","volume":"36","author":"Soljanlahti","year":"2005","journal-title":"Stroke"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"100344","DOI":"10.1016\/j.ensci.2021.100344","article-title":"Familial hypercholesterolemia and statins in the COVID-19 era: mitigating the risk of ischemic stroke","volume":"23","author":"Vuorio","year":"2021","journal-title":"ENeurologicalSci"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.jacc.2021.08.021","article-title":"Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review","volume":"78","author":"Talasaz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1111\/bph.15166","article-title":"Statins: could an old friend help in the fight against COVID-19?","volume":"177","author":"Rodrigues-Diez","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R53-20250729","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1161\/ATVBAHA.120.315551","article-title":"Beneficial effect of statins in COVID-19-related outcomes\u2014brief report","volume":"41","author":"Lee","year":"2021","journal-title":"Arterioscler Thromb Vascular Biol"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.21037\/apm-21-3464","article-title":"The association between statin and COVID-19 adverse outcomes: national COVID-19 cohort in South Korea","volume":"11","author":"Chow","year":"2022","journal-title":"Ann Palliat Med"},{"key":"R55-20250729","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1038\/s41598-022-09845-y","article-title":"Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis","volume":"12","author":"Ghosh","year":"2022","journal-title":"Sci Rep"},{"key":"R56-20250729","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-021-21553-1","article-title":"Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19","volume":"12","author":"Gupta","year":"2021","journal-title":"Nat Com"},{"key":"R57-20250729","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14779072.2022.2058490","article-title":"Il-6, Il-1\u03b2 and cytokine-targeted therapy for COVID -19 patients: two more reasons to take into account statins?","volume":"20","author":"Mormile","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R58-20250729","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.amjcard.2022.04.045","article-title":"Preadmission statin treatment and outcome in patients hospitalized with COVID-19","volume":"177","author":"Saad","year":"2022","journal-title":"Am J Cardiol"},{"key":"R59-20250729","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1038\/s41598-022-16357-2","article-title":"Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study","volume":"12","author":"Santosa","year":"2022","journal-title":"Sci Rep"},{"key":"R60-20250729","doi-asserted-by":"crossref","first-page":"e023357","DOI":"10.1161\/JAHA.121.023357","article-title":"Association of statins for primary prevention of cardiovascular diseases with hospitalization for COVID-19: a nationwide matched population-based cohort study","volume":"11","author":"Bouillon","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R61-20250729","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2020.06.006","article-title":"Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia","volume":"14","author":"Vuorio","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R62-20250729","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/joim.13210","article-title":"PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia","volume":"289","author":"Vuorio","year":"2021","journal-title":"J Intern Med"},{"key":"R63-20250729","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5114\/aoms.2020.94655","article-title":"Statins and the COVID-19 main protease: in silico evidence on direct interaction","volume":"16","author":"Reiner","year":"2020","journal-title":"Arch Med Sci"},{"key":"R64-20250729","doi-asserted-by":"crossref","first-page":"820131","DOI":"10.3389\/fimmu.2022.820131","article-title":"Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts","volume":"13","author":"Teixeira","year":"2022","journal-title":"Front Immunol"},{"key":"R65-20250729","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R66-20250729","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1172\/JCI137536","article-title":"Dengue virus induces PCSK9 expression to alter antiviral responses and diseases outcomes","volume":"130","author":"Gan","year":"2020","journal-title":"J Clin Invest"},{"key":"R67-20250729","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jacc.2022.11.014","article-title":"PCSK9: the nexus of lipoprotein metabolism and inflammation in COVID-19","volume":"81","author":"Goonewardena","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R68-20250729","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.athplu.2021.08.001","article-title":"Familial Hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition","volume":"43","author":"Vuorio","year":"2021","journal-title":"Atheroscler Plus"},{"key":"R69-20250729","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019\u200aESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"R70-20250729","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"R71-20250729","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2020.09.008","article-title":"Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK","volume":"313","author":"Iqbal","year":"2020","journal-title":"Atherosclerosis"},{"key":"R72-20250729","doi-asserted-by":"crossref","first-page":"e68165","DOI":"10.7554\/eLife.68165","article-title":"Identification of drugs associated with reduced severity of COVID-19: a case-control study in a large population","volume":"10","author":"Israel","year":"2021","journal-title":"Elife"},{"key":"R73-20250729","doi-asserted-by":"crossref","first-page":"e79946","DOI":"10.7554\/eLife.79946","article-title":"Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and nonrandomized open label interventional study","volume":"12","author":"Ehrlich","year":"2023","journal-title":"Elife"},{"key":"R74-20250729","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41574-020-0353-9","article-title":"Endocrine and metabolic link to coronavirus infection","volume":"16","author":"Bornstein","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"R75-20250729","doi-asserted-by":"crossref","first-page":"1068.e3","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and preexisting type 2 diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab"},{"key":"R76-20250729","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/01902148.2015.1046200","article-title":"PPAR-\u03b1 activation reduced LPS-induced inflammation in alveolar epithelial cells","volume":"41","author":"Hecker","year":"2015","journal-title":"Exp Lung Res"},{"key":"R77-20250729","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s42255-022-00698-3","article-title":"A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019","volume":"4","author":"Chirinos","year":"2022","journal-title":"Nat Metab"},{"key":"R78-20250729","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.acx9605","article-title":"Antiviral pills could change pandemic's course","volume":"374","author":"Couzin-Frankel","year":"2021","journal-title":"Science"},{"key":"R79-20250729","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R81-20250729","doi-asserted-by":"crossref","DOI":"10.2217\/fvl-2022-0060","article-title":"Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid\u2122 therapy","author":"Vuorio","year":"2022","journal-title":"Future Virol"},{"key":"R82-20250729","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/cid\/ciac667","article-title":"Statin needs to be continued during Paxlovid therapy in COVID-19","volume":"75","author":"Vuorio","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R83-20250729","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2022.11.039","article-title":"Drug-drug interaction with oral antivirals for the early treatment of COVID-19","volume":"127","author":"Vuorio","year":"2023","journal-title":"Int J Infect Dis"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:04:13Z","timestamp":1753826653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000876","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"type":"print","value":"0957-9672"},{"type":"electronic","value":"1473-6535"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}